CTLA4 and neoplasm: The suggested immunotherapeutic strategies, which are known as immune checkpoint inhibitors (ICIs), target and block the inhibitory T-cell receptor PD-1 or cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to restore tumor-specific T-cell immunity [10].